Logo image of NMTC

NEUROONE MEDICAL TECHNOLOGIE (NMTC) Stock Fundamental Analysis

NASDAQ:NMTC - Nasdaq - US64130M2098 - Common Stock - Currency: USD

1.15  +0.03 (+2.68%)

After market: 1.16 +0.01 (+0.87%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NMTC. NMTC was compared to 190 industry peers in the Health Care Equipment & Supplies industry. NMTC may be in some trouble as it scores bad on both profitability and health. NMTC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NMTC has reported negative net income.
In the past year NMTC has reported a negative cash flow from operations.
In the past 5 years NMTC always reported negative net income.
NMTC had a negative operating cash flow in each of the past 5 years.
NMTC Yearly Net Income VS EBIT VS OCF VS FCFNMTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -110.68%, NMTC is doing worse than 86.70% of the companies in the same industry.
The Return On Equity of NMTC (-244.88%) is worse than 79.79% of its industry peers.
Industry RankSector Rank
ROA -110.68%
ROE -244.88%
ROIC N/A
ROA(3y)-151.28%
ROA(5y)-173.14%
ROE(3y)-597.49%
ROE(5y)-520.66%
ROIC(3y)N/A
ROIC(5y)N/A
NMTC Yearly ROA, ROE, ROICNMTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K -2K

1.3 Margins

With a decent Gross Margin value of 65.61%, NMTC is doing good in the industry, outperforming 68.09% of the companies in the same industry.
NMTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMTC Yearly Profit, Operating, Gross MarginsNMTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

3

2. Health

2.1 Basic Checks

NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NMTC has more shares outstanding
Compared to 5 years ago, NMTC has more shares outstanding
The debt/assets ratio for NMTC is higher compared to a year ago.
NMTC Yearly Shares OutstandingNMTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NMTC Yearly Total Debt VS Total AssetsNMTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

NMTC has an Altman-Z score of -11.14. This is a bad value and indicates that NMTC is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NMTC (-11.14) is worse than 80.32% of its industry peers.
NMTC has a Debt/Equity ratio of 0.60. This is a neutral value indicating NMTC is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.60, NMTC is not doing good in the industry: 66.49% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z -11.14
ROIC/WACCN/A
WACC8.91%
NMTC Yearly LT Debt VS Equity VS FCFNMTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

NMTC has a Current Ratio of 3.64. This indicates that NMTC is financially healthy and has no problem in meeting its short term obligations.
NMTC has a better Current ratio (3.64) than 65.43% of its industry peers.
A Quick Ratio of 2.41 indicates that NMTC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.41, NMTC is in line with its industry, outperforming 57.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.64
Quick Ratio 2.41
NMTC Yearly Current Assets VS Current LiabilitesNMTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

4

3. Growth

3.1 Past

NMTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.47%, which is quite impressive.
Looking at the last year, NMTC shows a very strong growth in Revenue. The Revenue has grown by 205.91%.
Measured over the past years, NMTC shows a very strong growth in Revenue. The Revenue has been growing by 143.22% on average per year.
EPS 1Y (TTM)61.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%142.86%
Revenue 1Y (TTM)205.91%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%234.48%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year90%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NMTC Yearly Revenue VS EstimatesNMTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
NMTC Yearly EPS VS EstimatesNMTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NMTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NMTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMTC Price Earnings VS Forward Price EarningsNMTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMTC Per share dataNMTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NMTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROONE MEDICAL TECHNOLOGIE

NASDAQ:NMTC (2/21/2025, 8:00:01 PM)

After market: 1.16 +0.01 (+0.87%)

1.15

+0.03 (+2.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12 2025-02-12/bmo
Earnings (Next)05-12 2025-05-12/amc
Inst Owners16.79%
Inst Owner Change-96.33%
Ins Owners11.08%
Ins Owner Change-0.31%
Market Cap35.49M
Analysts43.33
Price TargetN/A
Short Float %0.57%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)62.01%
Min EPS beat(2)-34.8%
Max EPS beat(2)158.82%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-17.91%
Min Revenue beat(2)-88.49%
Max Revenue beat(2)52.66%
Revenue beat(4)1
Avg Revenue beat(4)-28.94%
Min Revenue beat(4)-88.49%
Max Revenue beat(4)52.66%
Revenue beat(8)4
Avg Revenue beat(8)6.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.06
P/FCF N/A
P/OCF N/A
P/B 12.09
P/tB 12.35
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.28
BVpS0.1
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.68%
ROE -244.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.61%
FCFM N/A
ROA(3y)-151.28%
ROA(5y)-173.14%
ROE(3y)-597.49%
ROE(5y)-520.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.35
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.44%
Cap/Sales 1.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.64
Quick Ratio 2.41
Altman-Z -11.14
F-Score4
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)158.27%
Cap/Depr(5y)160.46%
Cap/Sales(3y)9.28%
Cap/Sales(5y)12.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%142.86%
EPS Next Y33.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)205.91%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%234.48%
Revenue Next Year90%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y49.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.03%
OCF growth 3YN/A
OCF growth 5YN/A